New Zealand’s Drug Development Industry

• Main Authors: Christopher Carswell, Sanjay Garg, Zaheer-Ud-Din Babar, Michelle Marie Lockhart
• Format: Article
• Language: English
• Published: MDPI AG 2013-09-01
• Series: International Journal of Environmental Research and Public Health
• Subjects: drug development; economic benefits; New Zealand; clinical research; drug discovery
• Online Access: http://www.mdpi.com/1660-4601/10/9/4339

The pharmaceutical industry’s profitability depends on identifying and successfully developing new drug candidates while trying to contain the increasing costs of drug development. It is actively searching for new sources of innovative compounds and for mechanisms to reduce the enormous costs of developing new drug candidates. There is an opportunity for academia to further develop as a source of drug discovery. The rising levels of industry outsourcing also provide prospects for organisations that can reduce the costs of drug development. We explored the potential returns to New Zealand (NZ) from its drug discovery expertise by assuming a drug development candidate is out-licensed without clinical data and has anticipated peak global sales of $350 million. We also estimated the revenue from NZ’s clinical research industry based on a standard per participant payment to study sites and the number of industry-sponsored clinical trials approved each year. Our analyses found that NZ’s clinical research industry has generated increasing foreign revenue and appropriate policy support could ensure that this continues to grow. In addition the probability-based revenue from the out-licensing of a drug development candidate could be important for NZ if provided with appropriate policy and financial support.